Immune killer cell therapy (Ivy Life Sciences)

免疫杀伤细胞疗法（Ivy Life Sciences）

Report date: 2025/02/16 20:00:06

Base Information

Drug NameImmune killer cell therapy (Ivy Life Sciences)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsLiver Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwan
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIvy Life Sciences Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIvy Life Sciences Co Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung NeoplasmsLiver Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A